In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

The U.S. Food and Drug Administration said last week it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ... for its ambitious drug pipeline that involves winning FDA approval ...

(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making ...